Purchase Order 36C26122P0572
Award Date
2/9/22
Potential Completion Date
9/30/22
Potential Value
$110K
Federal Agency
Veterans Integrated Service Network 21
Awardee
Foundation Care LLC
Ultimate Awardee
Centene Corporation
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Palo Alto, CA 94304, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 8 to Foundation Care LLC, a for-profit specialty pharmacy and subsidiary of Centene Corporation. The $5,390.00 contract is for the delivery of pain management components, with an ultimate completion date of November 15, 2015. The contract does not have a set-aside designation. Foundation Care LLC is a critical supplier of specialized pharmaceutical products,...
Foundation Care LLC, a for-profit specialty pharmacy and subsidiary of Centene Corporation, has been awarded a $24,538.70 firm fixed price purchase order contract by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 located in Palo Alto, California. The contract is for the provision of Iclusig (ponatinib), a medication used to treat certain types of leukemia and blood disorders. Performance will take place in Palo Alto and be completed by...
This is a firm-fixed-price delivery order contract awarded by the Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract has a ceiling value of $69,783.60 and supports the delivery of the oncology medication ICLUSIG (ponatinib) to VA medical facilities nationwide through September 2024. The contract is issued under Takeda's existing General Services Administration (GSA) Schedule 61-IB for...
The U.S. Department of Veterans Affairs (VA) awarded a $173,208.96 firm-fixed-price delivery order contract to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, to provide bulk orders of the oncology medication ICLUSIG (ponatinib). The contract was issued against Takeda's existing General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs and supports the VA's provision of specialized cancer treatments to veterans nationwide....
This federal contract award is for the delivery of the cancer drug Iclusig (ponatinib) to the Department of Veterans Affairs Veterans Health Administration. The contract was awarded to the prime contractor Ariad Pharmaceuticals, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products. The contract was not set aside and was awarded under the General Services Administration (GSA) Pharmaceuticals and Drugs schedule, which allows government agencies to purchase drugs and...
This contract is a delivery order issued by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 20 for the purchase of Ponatinib (Iclusig) 15mg tablets for the Seattle VA Medical Center. The contract was awarded to Ariad Pharmaceuticals, Inc., a pharmaceutical company owned by Takeda Pharmaceutical Company Limited. The contract is a Blanket Purchase Agreement (BPA) call under the General Services Administration (GSA) Pharmaceutical and...
The Department of Veterans Affairs (VA) Veterans Health Administration awarded a $27,913.44 firm-fixed-price delivery order contract to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, to provide the oncology drug ICLUSIG (ponatinib) to VA medical facilities. This delivery order falls under Takeda's existing General Services Administration (GSA) Multiple Award Schedule contract for Pharmaceuticals and Drugs. The contract has a period of performance...
This is a firm fixed-price Blanket Purchase Agreement (BPA) call issued by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 7 (VISN 7) to Ariad Pharmaceuticals, Inc. for the order of pharmaceuticals, specifically cancer drugs such as Iclusig (ponatinib) and Lenvima (lenvatinib), for the Department of Veterans Affairs in fiscal year 2017. The contract has a ceiling value of $108,039.90 and an ultimate completion date of September 30, 2017. This contract was awarded...
This federal contract was awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Ariad Pharmaceuticals, Inc., a pharmaceutical company that provides cancer drugs through the GSA Pharmaceuticals and Drugs schedule. The contract is for the delivery of the cancer drug Iclusig (ponatinib) to VA hospitals and medical centers under Veterans Integrated Service Network 7. The contract was not set aside and has a potential value of $148,782.16. The contract is a BPA...
This is a delivery order contract awarded by the Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, based in Japan. The contract is for the supply of ICLUSIG 15 MG, a specialty oncology medication used to treat certain types of leukemia. The contract has a firm-fixed-price pricing type and a ceiling value of $13,956.72, with an ultimate completion date of December 10, 2024....